MEDVi review

MEDVi makes getting started look simple: fill in an online health assessment, pay, then have a clinician decide whether a prescription is appropriate. Its current offer includes medication, physician review, a personalized plan and delivery. The clinical work is attributed to OpenLoop Health and CareGLP affiliated practices rather than MEDVi itself. The public site also names three partner pharmacies, Triad Rx, RedRock Pharmacy and Beaker Pharmacy & Compounding, with addresses and phone numbers. That is useful transparency, although it does not tell you which pharmacy would fill your particular order before the clinician chooses treatment.

The $179 headline is a first-month semaglutide offer, not the continuing price. The FAQ sets refills at $299, so twelve monthly purchases at those disclosed rates would total $3,468 if the offer and treatment remain unchanged. Dissolving GLP-1 tablets start at $249, but the public page does not give a matching ongoing price. Branded Wegovy pills, Wegovy injections and Zepbound use another structure: a $99 membership plus the medication. Do not compare that membership alone with an all-in compounded price. The dietitian and coaching benefit also carries an insurance-and-copay eligibility footnote.

The refund policy deserves more attention than the guarantee banner. Cancellation is available through support or portal chat, but the request must arrive at least 72 hours before the next billing date. Monthly charges already paid generally are not refunded. The policy describes exceptions for medical disqualification and an unused subscription canceled within its first 72 hours, yet later uses a broad statement limiting refunds to medical disqualification. Ask for written clarification of the exception that applies to you before paying, particularly on a prepaid program.

There is also a real regulatory concern. In February 2026 the FDA sent MEDVi, LLC a warning letter about misleading advertising of compounded semaglutide and tirzepatide, including implications about approval and who made the drugs. The letter identifies the same Newark mailing address currently shown by MEDVi. It is an enforcement warning, not a finding that every prescription causes harm, but it matters when judging marketing credibility. The current site says compounded drugs are not FDA-approved, and its patient-reported weight-loss claims should not be treated as equivalent to results from trials of approved medicines.